PIXY321 fusion protein, recombinant

Known as: PIXY321, PIXY321 protein, recombinant, pIXY 321 protein, recombinant 
 

Topic mentions per year

Topic mentions per year

1991-2005
02419912005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
CD34(+) cells and megakaryocyte progenitors were lower in marrow from patients after hematological recovery from the first cycle… (More)
Is this relevant?
1999
1999
This dose-escalation study was performed to evaluate the hematologic activity, biological effects, immunogenicity, and toxicity… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
1999
1999
PURPOSE To measure the effect of PIXY321 (granulocyte-macrophage colony-stimulating factor/interleukin-3 S. cerevisiae fusion… (More)
Is this relevant?
1998
1998
Fourteen paediatric patients with advanced amegakaryocytic thrombocytopenia (AMT) or other bone marrow (BM) failure syndromes… (More)
Is this relevant?
1996
1996
PURPOSE Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the… (More)
Is this relevant?
1996
1996
Studies with the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin-3 (IL-3) fusion protein, PIXY321… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
1996
1996
PURPOSE A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) was… (More)
Is this relevant?
1995
1995
PIXY321 is a novel fusion protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 that… (More)
Is this relevant?
1994
1994
PURPOSE To evaluate the clinical safety and ability of PIXY321, a novel fusion protein of recombinant human granulocyte… (More)
Is this relevant?
1992
1992
ABSTRACT: Two novel cytokines, stem cell factor (SCF) and PIXY321 (a fusion protein, granulocyte macrophage colony-stimulating… (More)
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?